Strategic partnerships Erasca seeks to expand its pipeline through partnerships with academic scientists and biopharmaceutical companies, presenting a steady sales opportunity for collaboration agreements, licensing, and co-development deals with external researchers and potential buyers.

Clinical collaboration Recent activity includes a Merck collaboration to evaluate ERAS-0015 with KEYTRUDA, indicating openness to in-therapy partnerships and combination strategy deals which could extend to additional IO and targeted therapy partners.

Product expansion With undisclosed initial targets and a non-single approach to treating cancer, there is opportunity to position diagnostic, biomarker, or companion assay offerings alongside Erasca’s therapies to support precision oncology programs.

IP and risk signals Industry activity includes patent and data-related disputes and investigations, suggesting a need for rigorous IP due diligence services, competitive landscape analyses, and robust data integrity tooling for prospective partners.

Funding and scale fit Holds substantial funding and mid-to-large scale revenue, aligning with mid-market to strategic pharma partnerships for later-stage programs, co-development, or market access collaborations as Erasca scales.